Information concerning registration for the LRA 2026 conference, which will include a keynote address by Dr. Yolanda Sealey-Ruiz, is expected to be released shortly on the Literacy Research ...

My academic funding was running out and my patience with the delirious pace of start-up culture had run thin. You might say I got fired; I might reply that I was never really hired in the first place.

Blessing, E. (2026) A Strategic Analysis of Nigeria’s Hedging Strategy in the Context of U.S.-China Rivalry. Open Journal of Business and Management, 14, 884-900. doi: 10.4236/ojbm.2026.142051 .

The AI Agent Crisis” draws on Carnegie Mellon, MIT, and RAND research to present the first comprehensive framework for ...

Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.90, marking a -4.88% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.51% for ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...